The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of HX008 for the Treatment of Patients With Malignant Melanoma
Official Title: A Single-armed Open-labeled Phase II Study of HX008 (a Humanized Monoclonal Antibody Targeting PD-1) for the Treatment of Patients With Locally Advanced or Metastatic Melanoma Who Have Failed the Standard Treatments.
Study ID: NCT04749485
Brief Summary: HX008 is a humanized monoclonal antibody targeting PD-1 on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors. In this study, the efficacy and safety of HX008 in patients with locally advanced or metastatic melanoma who have failed the standard treatments will be evaluated.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Peking University Cancer Hospital and Research Institute, Beijing, Beijing, China
Fujian Cancer Hospital, Fuzhou, Fujian, China
The First Affiliated Hospital of Jinan University, Guangzhou, Guangdong, China
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
Nanjing Drum Tower Hospital, Nanjing, Jiangsu, China
The first Hospital of Jilin University, Changchun, Jilin, China
Fudan Universtiy Shanghai Cancer Center, Shanghai, Shanghai, China
Shanghai Tenth People's Hospital, Shanghai, Shanghai, China
West China Hospital Sichuan Universtiy, Chengdu, Sichuan, China
The Affiliated Cancer Hospital of Xinjiang Medical University, Ürümqi, Xinjiang, China
Zhejiang University School of Medicine Sir Run Run Shaw Hospital, Hangzhou, Zhejiang, China
Name: Jun Guo, MD
Affiliation: Peking University Cancer Hospital and Research Institute
Role: STUDY_CHAIR